FDA orders GLP-1 makers to add warning on rare 'eye stroke' risk

The Food and Drug Administration (FDA) on Monday required drug companies to warn patients and health care providers of a potential increased risk of a serious eye condition tied to GLP-1 drugs used for weight loss and diabetes ¹.

The condition is called non-arteritic anterior ischemic optic neuropathy, or NAION. It is often called an "eye stroke." It is rare, but it can cause sudden, painless vision loss in one eye, including permanent loss ¹.

What the FDA found

NAION is caused by a sudden reduction or blockage of blood flow to the front part of the optic nerve ¹. The optic nerve carries signals from the eye to the brain. The condition is permanent, with no known treatment ².

The FDA said cases have been reported for all GLP-1 products now on the market. That includes Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound ¹. The rule also covers several older GLP-1 diabetes drugs ².

Companies must add the risk to the "warnings and precautions" section of the drug label ¹. If the condition has struck one eye, the risk that it will strike the other eye is higher, the FDA said ¹.

The agency began its review after a 2024 study in JAMA Ophthalmology. It found diabetes patients prescribed semaglutide, the drug in Ozempic and Wegovy, were four times as likely to develop NAION as those not prescribed it ². The FDA noted "several limitations" in that study but said more review was warranted ¹.

FDA scientists could not identify how the drugs might raise the risk ². Other risk factors, including Type 2 diabetes, obesity, sleep apnea and high blood pressure, overlap with conditions seen in people who take GLP-1s ².

What doctors say

Dr. Manjot Gill, an ophthalmologist at Northwestern Medicine in Chicago, said the warning label is appropriate. She said it is well documented that the drugs may increase the risk, though it is unclear whether they cause the condition ².

We don’t want patients to really get overly concerned and anxious and to stop these medications,

Spokespeople for Novo Nordisk and Eli Lilly said patient safety is their top priority ².

Why it matters for older readers

That matters because NAION is the second most common optic nerve disease in the U.S. It occurs in up to 10 out of 100,000 people over age 50, according to the American Academy of Ophthalmology ². Many people in that age group also have diabetes, obesity or high blood pressure ².

The labels already carry other warnings, including for pancreatitis, gallbladder problems and kidney injury. They also carry a black box warning, the FDA's strongest, about a possible risk of thyroid tumors ².

The articles did not say when the new labels will appear. Patients on these drugs should not stop taking them on their own. They should talk with their doctor about their own risks.

The Record

1. Jan 1, 2024A study in JAMA Ophthalmology found diabetes patients prescribed semaglutide were four times as likely to develop NAION as those not prescribed it; the FDA began its review afterward ².
2. Nov 9, 2026The FDA required all GLP-1 makers to add NAION risk to the warnings and precautions section of drug labels ¹².

Free to reprint Republish this story on your site or in your newsletter

Any site, blog or newsletter may run this story free of charge. Keep the credit line and its link to the original, do not sell it, and edit only for length or house style (the full terms). Photos carry their own licenses, noted under each photo on this page, so use the text alone unless a credit says otherwise.

<h2>FDA orders GLP-1 makers to add warning on rare &#39;eye stroke&#39; risk</h2> <p><em>By The GOP Files Kitchen-Table Desk. This article first appeared on <a href="https://thegopfiles.com/story/fda-orders-glp-1-makers-to-add-warning-on-rare-eye-stroke-risk">The GOP Files</a> on Monday, November 9, 2026.</em></p> <p>The Food and Drug Administration (FDA) on Monday required drug companies to warn patients and health care providers of a potential increased risk of a serious eye condition tied to GLP-1 drugs used for weight loss and diabetes .</p> <p>The condition is called non-arteritic anterior ischemic optic neuropathy, or NAION. It is often called an &quot;eye stroke.&quot; It is rare, but it can cause sudden, painless vision loss in one eye, including permanent loss .</p> <h2>What the FDA found</h2> <p>NAION is caused by a sudden reduction or blockage of blood flow to the front part of the optic nerve . The optic nerve carries signals from the eye to the brain. The condition is permanent, with no known treatment .</p> <p>The FDA said cases have been reported for all GLP-1 products now on the market. That includes Novo Nordisk&#39;s Ozempic and Wegovy and Eli Lilly&#39;s Mounjaro and Zepbound . The rule also covers several older GLP-1 diabetes drugs .</p> <p>Companies must add the risk to the &quot;warnings and precautions&quot; section of the drug label . If the condition has struck one eye, the risk that it will strike the other eye is higher, the FDA said .</p> <p>The agency began its review after a 2024 study in JAMA Ophthalmology. It found diabetes patients prescribed semaglutide, the drug in Ozempic and Wegovy, were four times as likely to develop NAION as those not prescribed it . The FDA noted &quot;several limitations&quot; in that study but said more review was warranted .</p> <p>FDA scientists could not identify how the drugs might raise the risk . Other risk factors, including Type 2 diabetes, obesity, sleep apnea and high blood pressure, overlap with conditions seen in people who take GLP-1s .</p> <h2>What doctors say</h2> <p>Dr. Manjot Gill, an ophthalmologist at Northwestern Medicine in Chicago, said the warning label is appropriate. She said it is well documented that the drugs may increase the risk, though it is unclear whether they cause the condition .</p> <blockquote><p>We don’t want patients to really get overly concerned and anxious and to stop these medications,</p><p>&mdash; Manjot Gill, ophthalmologist, Northwestern Medicine</p></blockquote> <p>Spokespeople for Novo Nordisk and Eli Lilly said patient safety is their top priority .</p> <h2>Why it matters for older readers</h2> <p>That matters because NAION is the second most common optic nerve disease in the U.S. It occurs in up to 10 out of 100,000 people over age 50, according to the American Academy of Ophthalmology . Many people in that age group also have diabetes, obesity or high blood pressure .</p> <p>The labels already carry other warnings, including for pancreatitis, gallbladder problems and kidney injury. They also carry a black box warning, the FDA&#39;s strongest, about a possible risk of thyroid tumors .</p> <p>The articles did not say when the new labels will appear. Patients on these drugs should not stop taking them on their own. They should talk with their doctor about their own risks.</p> <p><em>Read the original, with every source linked, at <a href="https://thegopfiles.com/story/fda-orders-glp-1-makers-to-add-warning-on-rare-eye-stroke-risk">thegopfiles.com</a>. Republished under The GOP Files' <a href="https://thegopfiles.com/republish">free republishing terms</a>.</em></p> <img src="https://thegopfiles.com/api/rp/fda-orders-glp-1-makers-to-add-warning-on-rare-eye-stroke-risk.gif" alt="" width="1" height="1" style="border:0;width:1px;height:1px">

Copy the HTML Paste it into your editor's HTML view. The one-pixel image at the end tells our newsroom the story ran; it stores no reader data.

Sources

1. The Hill, “FDA warns of rare 'eye stroke' risk from GLP-1 drugs” (2026-11-09). thehill.com/policy/healthcare/6209047-fda-glp1-drug-nainon-r
2. NBC News, “FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness” (2026-11-09). nbcnews.com/health/health-care/fda-orders-new-warning-glp-1s

Found an error? Tell the newsroom. Corrections are noted at the top of the story.